Trials / Completed
CompletedNCT06645704
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Escient Pharmaceuticals, Inc · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is being conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\]-EP262 in healthy male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EP262 | Single dose of \[14C\]-EP262 administered orally. |
Timeline
- Start date
- 2024-10-01
- Primary completion
- 2024-12-10
- Completion
- 2024-12-10
- First posted
- 2024-10-17
- Last updated
- 2025-02-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06645704. Inclusion in this directory is not an endorsement.